In agreement with this statement, treatment of CD4+ osteoblasts with the glucosylceramide synthase inhibitor 1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol (PPMP) has been shown to significantly alter the susceptibility of these cells to HIV-1 infection. Here, UGCG is linked to HIV-1 infection.